Repare Therapeutics Inc. to Post FY2025 Earnings of ($2.79) Per Share, Bloom Burton Forecasts (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX) – Equities research analysts at Bloom Burton issued their FY2025 earnings per share estimates for shares of Repare Therapeutics in a research report issued on Thursday, September 12th. Bloom Burton analyst D. Martin anticipates that the company will post earnings per share of ($2.79) for the year. The consensus estimate for Repare Therapeutics’ current full-year earnings is ($2.31) per share.

Several other analysts have also weighed in on the company. Lifesci Capital raised Repare Therapeutics to a “strong-buy” rating in a report on Monday, July 29th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a report on Wednesday, September 4th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Repare Therapeutics has an average rating of “Buy” and an average price target of $17.33.

Repare Therapeutics Trading Up 17.7 %

Shares of NASDAQ:RPTX opened at $3.53 on Friday. Repare Therapeutics has a 1-year low of $2.71 and a 1-year high of $13.85. The firm has a market capitalization of $149.83 million, a PE ratio of -3.21 and a beta of 0.71. The business’s 50 day moving average is $3.26 and its 200-day moving average is $3.78.

Repare Therapeutics (NASDAQ:RPTX) last released its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.03. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $4.02 million. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%.

Hedge Funds Weigh In On Repare Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can lifted its position in shares of Repare Therapeutics by 5.4% during the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock worth $366,000 after buying an additional 5,673 shares during the period. XTX Topco Ltd bought a new position in Repare Therapeutics in the 2nd quarter valued at $110,000. Jump Financial LLC bought a new position in Repare Therapeutics in the 4th quarter valued at $289,000. Acadian Asset Management LLC raised its position in Repare Therapeutics by 53.5% in the 1st quarter. Acadian Asset Management LLC now owns 133,893 shares of the company’s stock valued at $625,000 after purchasing an additional 46,648 shares during the last quarter. Finally, Opaleye Management Inc. bought a new position in Repare Therapeutics in the 1st quarter valued at $318,000. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.